Intellia Therapeutics, Inc.

Good morning and welcome to the Intellia Therapeutics first quarter 2023 financial results conference call. My name is Drew and I will be your conference operator today. Following formal remarks, we will open the call up for a question and answer session. This conference is being recorded at the company's request and will be available on the company's website following the end of the call. As a reminder, all participants are currently in listen only mode. I will now turn the conference over to Ian Karp, Senior Vice President of Investor Relations and Corporate Communications at Intelia. Please proceed.

Thank you, Operator, and good morning, everyone. Welcome to Intelia Therapeutics' first quarter 2023 earnings call. Earlier this morning, Intelia issued a press release outlining the company's progress this quarter, as well as topics for discussion on today's call. This release can be found on the investor and media section of Intelia's website, at intelliatx.com. This call is being broadcast live, and a replay will be archived on the company's website. At this time, I would like to take a minute to remind listeners that during this call, Intellia management may make certain forward-looking statements and ask that you refer to our SEC filings available at sec.gov for discussion of potential risks and uncertainties. All information presented on this call is current as of today, and Intellia undertakes no duty to update this information unless required by law. Joining me from Intelia are Dr. John Leonard, Chief Executive Officer, Dr. David Lebwall, Chief Medical Officer, and Glenn Goddard, Chief Financial Officer. John will begin with an overview of recent business highlights, David will provide an update on our clinical programs, and Glenn will review financial results for the first quarter of 2023 before we open up the call for Q&A, at which time Dr. Laura Sepp-Lorenzino, our Chief Scientific Officer, will also be available. With that, I'll now turn the call over to John.

Thank you, Ian, and thank you all for joining us this morning. At Intelia, we're continuing to lead the genome editing revolution with the broadest and deepest toolbox of novel editing and delivery solutions. We've had a productive start to the year in the recent successful clearance of our first IND for an investigational in vivo CRISPR-based therapy. Alongside that regulatory accomplishment, we continue to make important progress across both our in vivo and ex vivo pipeline and platform. Today, we're pleased to announce dosing has begun in the Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema, or HAE. Additionally, based on strong interest from investigators and patients, we expect to complete study enrollment in the second half of this year. Both the FDA's acceptance of our IND application and the rapid clinical progression of NTLA-2002 move us one step closer to our goal of introducing a potential functional cure for people living with HAE. Simultaneously, we're working towards submitting our second in vivo IND. This next IND is for the planned pivotal trial of NTLA-2001 for people with the cardiomyopathy manifestation of ATTR amyloidosis. Some estimates indicate there may be as many as 500,000 people who suffer from this disease around the world. Subject to regulatory feedback, we expect to initiate the global pivotal trial by year end. Both NTLA-2001 and NTLA-2002 represent potentially paradigm shifting treatments as supported by the initial groundbreaking clinical data presented last year. As the first and only company to demonstrate successful systemic CRISPR gene editing in humans to date, we now look forward to presenting new interim data from each phase one study at upcoming medical meetings later this year. Lastly, we're very happy to welcome Bill Chase to our Board of Directors. Bill brings over three decades of financial management expertise and a strong track record for building leading biopharmaceutical companies. He was formerly the CFO of AbbVie and spearheaded its successful spin-out from Abbott Laboratories. Bill will succeed Carolyn Dorsa as Audit Committee Chair following her retirement from the Board. I would also like to take this opportunity to thank Carolyn Dorsa for her long and dedicated service on Intellia's board and her many contributions to the company's growth and success as its first independent director. We wish her well in her future pursuits. With that summary of the excellent progress we've made so far this year, I'll hand the call over to our Chief Medical Officer, David Leblal, who will review the lead clinical programs in greater detail. David?